PeriGen

Executive Summary

PeriGen is a privately held digital health company specializing in AI-driven perinatal software solutions designed to improve maternal and fetal outcomes during labor and delivery. Founded in 2008 and headquartered in Princeton, NJ, the company offers two core products: PeriWatch Surveillance, an electronic fetal monitoring and documentation system, and PeriWatch Vigilance, the only automated Early Warning System (EWS) for labor and delivery. These systems leverage machine learning to analyze real-time patient data, alerting clinicians to signs of potential complications such as maternal hemorrhage or fetal distress. By integrating seamlessly into hospital workflows, PeriGen aims to reduce preventable adverse events, lower C-section rates, and enhance overall patient safety. The company operates in the growing digital health market, with increasing demand for AI-assisted clinical decision support tools. While financial details and funding history are not publicly disclosed, PeriGen's focus on high-acuity obstetrics positions it as a key player in a niche but critical segment. With regulatory clearances and adoption in numerous U.S. hospitals, the company is poised for expansion as healthcare systems prioritize value-based care and technology-driven risk mitigation. However, competition from larger health IT vendors and the need to demonstrate robust clinical evidence remain challenges.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for next-generation PeriWatch platform80% success
• Q1 2027Major health system partnership for PeriWatch Vigilance deployment60% success
• Q2 2027Publication of multi-site clinical study demonstrating improved outcomes70% success